Data Presented At San Antonio Breast Cancer Symposium Demonstrate Treatment With Deno

[News]

Amgen (NASDAQ:AMGN) announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer...

More... (http://www.medicalnewstoday.com/articles/173686.php)